DNA Binding to Mouse Cells is Mediated by Cell-surface Molecules: the Role of These DNA-binding Molecules As Target Antigens in Murine Lupus
Overview
Affiliations
Autoimmunity to a 28-29-kDa cell-surface DNA-binding molecule has previously been described in patients with systemic lupus erythematosus and related autoimmune diseases. This report describes experiments that implicate a similar antigen-antibody system in the evolution of autoimmunity in lupus-prone mice. DNA binding to murine spleen cells was found to be a saturable phenomenon that was inhibited by excess cold DNA and trypsinization. The role of autoimmunity to murine cell-surface DNA-binding molecules in lupus-prone mice (MRL lpr/lpr, MRL +/+, BXSB) was compared to normal mice (BALB/c, C3H.SW) by means of an assay that measured the inhibition of cell-surface DNA binding. Only sera from lupus strains had inhibitory activity and this component was shown to be an IgM autoantibody. Furthermore, we isolated a spontaneously occurring IgM monoclonal antibody from the spleen of an MRL/lpr mouse, which inhibited DNA binding to mouse cells. Time-course studies indicated that young female MRL/lpr mice lacked detectable activity against cell-surface DNA-binding molecules; however, by 8-10 weeks maximal inhibitory activity was observed. This response occurred prior to the development of significant antinuclear antibody activity. With the appearance of overt disease and anti-DNA antibodies, inhibition of DNA-binding activity became undetectable. These findings mirror previous studies on autoimmunity to a cell-surface DNA-binding molecule on human leucocytes, but have the added advantage of permitting the study of the temporal evolution of this inhibitory activity in relation to disease expression.
Cell separation: Terminology and practical considerations.
Tomlinson M, Tomlinson S, Yang X, Kirkham J J Tissue Eng. 2013; 4:2041731412472690.
PMID: 23440031 PMC: 3578272. DOI: 10.1177/2041731412472690.
Servais G, Guillaume M, Dumarey N, Duchateau J Ann Rheum Dis. 1999; 57(10):606-13.
PMID: 9893572 PMC: 1752489. DOI: 10.1136/ard.57.10.606.
Genetic vaccines: strategies for optimization.
Gregoriadis G Pharm Res. 1998; 15(5):661-70.
PMID: 9619772 DOI: 10.1023/a:1011950415325.
Bennett R, Cornell K, Merritt M, Bakke A, Mourich D, Hefeneider S Clin Exp Immunol. 1992; 90(3):428-33.
PMID: 1333925 PMC: 1554583. DOI: 10.1111/j.1365-2249.1992.tb05863.x.